Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Completed · Phase 3 · Has a placebo group

Conditions studied: Refractory Generalized Myasthenia Gravis

In brief

The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.

Key facts

Study ID
NCT01997229
Run by
Alexion Pharmaceuticals, Inc.
People needed
125
Starts
2013-12-01
Expected to finish
2016-06-01
Last updated by the study team
2019-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.